Abiomed Inc. shares rose in the extended session Thursday after the medical device maker received Food and Drug Administration approval for its heart pumps. Abiomed shares advanced 3.7% to $99.20, following a brief after-hours halt. The company said the FDA approved four models of its Impella line of heart pumps to treat ongoing cardiogenic shock, or when the heart cannot pump enough blood to meet the needs of the body.
Continue Reading Below
Copyright © 2016 MarketWatch, Inc.